Results 161 to 170 of about 67,411 (205)

A Pharmacogenomic Basis for Tolerance of 5-Fluorouracil Following Early, Severe Toxicity from Capecitabine in a CDA Ultrarapid Metabolizer Colon Cancer Patient: A Case Report. [PDF]

Cancer Manag Res
Mazhindu TA, Chikwambi Z, Matsikidze E, Grimes KV, Borok MZ, Ndlovu N, Masimirembwa C, Consortium for Genomics and Therapeutics in Africa.   +7 more
europepmc   +1 more source

Safety and Tolerability of Different Total Neoadjuvant Therapies in Patients With Locally Advanced Rectal Cancer. [PDF]

Cancer Med
Udagawa S, Osumi H, Taguchi S, Noguchi T, Sakamoto T, Matsui S, Mukai T, Yamaguchi T, Fukuoka S, Yoshino K, Shimozaki K, Wakatsuki T, Ogura M, Ooki A, Chin K, Yamaguchi K, Akiyoshi T, Shinozaki E.   +17 more
europepmc   +1 more source

TBKBP1 induces capecitabine resistance through negative regulation of type I interferon pathway in triple-negative breast cancer. [PDF]

Oncogene
Wu WY, Yang YS, Andriani L, Xie YF, Di GH, Shao ZM, Li JJ.   +6 more
europepmc   +1 more source

Impact of Thiazides and Fluoropyrimidines Interaction on Myelotoxicity and Other Adverse Events in Real-World Practice: A Retrospective Cohort Study. [PDF]

Cancer Med
Ronda-Roca G, Porcel-Maleno J, Lobo-Palomar M, Centeno-Soto G, Ruiz-Casado A, Ruiz-Antorán B.   +5 more
europepmc   +1 more source

A review of the current evidence for maintenance therapy in gastric cancer. [PDF]

Front Pharmacol
Han X, Zhang Y, Fan Q, Yu J, Lv L, Li Y, Hou L.   +6 more
europepmc   +1 more source

Efficacy and Safety of Envafolimab Combined With Capecitabine and Lenvatinib as Postoperative Adjuvant Therapy in Resected Biliary Tract Cancer With High-Risk Recurrence Factors: A Phase II Single-Center Prospective Study. [PDF]

Cancer Med
Tian Y, Lei T, Ruan Q, Zhou X, Shen R, Xie T, Li S, Cai X, Chen M.   +8 more
europepmc   +1 more source

Real-World Effectiveness and Safety of Tucatinib, Trastuzumab, and Capecitabine in HER2-Positive Advanced Breast Cancer: A Multicenter Portuguese Study. [PDF]

Eur J Breast Health
Ferreira RQ, Monteiro CB, Dias AC, Abreu F, Darmits B, Oura MJ, Ângelo I, Cabral J, Figueiredo A, Ferreira R, Alpuim Costa D, Marques MT, Pina-Cabral T, Araújo F, Bento S, Fernandes CL, Santiago M, Silva B, Montenegro MA, Simão DC, Fernandes L, Oliveira SD.   +21 more
europepmc   +1 more source

Advances in the study of pyrotinib for the treatment of HER2-positive breast cancer. [PDF]

Breast Cancer Res
Li Y, Wang W, Liang Y, Lai H, Mi K, Zhang P, Zhang J, Wang Y.   +7 more
europepmc   +1 more source

Fosnetupitant for long-delayed chemotherapy-induced nausea and vomiting in oxaliplatin-based regimens: a prospective observational study (LODEC-N). [PDF]

Cancer Chemother Pharmacol
Iimura Y, Iihara H, Aoyama T, Hayashi T, Ishibashi M, Sasuga C, Furukawa N, Anzai E, Ijichi Y, Kuroda S.   +9 more
europepmc   +1 more source